These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36396615)

  • 1. Filgotinib in rheumatoid arthritis.
    Westhovens R
    Expert Rev Clin Immunol; 2023 Feb; 19(2):135-144. PubMed ID: 36396615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating filgotinib for the treatment of rheumatoid arthritis.
    Richez C; Truchetet ME
    Expert Opin Pharmacother; 2021 Dec; 22(18):2435-2444. PubMed ID: 34402699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
    Tanaka Y; Kavanaugh A; Wicklund J; McInnes IB
    Mod Rheumatol; 2022 Jan; 32(1):1-11. PubMed ID: 33740386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Filgotinib for the treatment of rheumatoid arthritis.
    Taylor PC; Abdul Azeez M; Kiriakidis S
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1181-1187. PubMed ID: 28838249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis.
    Mysler E; Lizarraga A
    Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii17-ii23. PubMed ID: 33950225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
    Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filgotinib as rheumatoid arthritis therapy.
    Becciolini A; Di Donato E; Santilli D; Lucchini G; Mozzani F; Riva M; Ariani A
    Drugs Today (Barc); 2021 Sep; 57(9):543-550. PubMed ID: 34586102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years.
    Burmester GR; Gottenberg JE; Caporali R; Winthrop KL; Tanaka Y; Ekoka Omoruyi EV; Rajendran V; Van Hoek P; Van Beneden K; Takeuchi T; Westhovens R; Aletaha D
    Ann Rheum Dis; 2024 Aug; 83(9):1110-1117. PubMed ID: 38782549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights.
    Raimondo MG; Biggioggero M; Coletto LA; Ramming A; Caporali R; Favalli EG
    Expert Rev Clin Pharmacol; 2021 Jun; 14(6):661-670. PubMed ID: 33847204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.
    Avci AB; Feist E; Burmester GR
    Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii11-ii16. PubMed ID: 33950228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry.
    Fornaro M; Caporali R; Biggioggero M; Bugatti S; De Stefano L; Cauli A; Congia M; Conti F; Chimenti MS; Bazzani C; Perniola S; Atzeni F; Lapadula G; Ferraccioli G; Iannone F;
    Clin Exp Rheumatol; 2024 May; 42(5):1043-1050. PubMed ID: 38634362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
    Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
    Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
    Meng A; Anderson K; Nelson C; Ni L; Chuang SM; Bellanti F; Chang P; Comisar C; Kearney BP; Bartok B; Mathias A
    Br J Clin Pharmacol; 2022 Jul; 88(7):3211-3221. PubMed ID: 35072287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
    Namour F; Diderichsen PM; Cox E; Vayssière B; Van der Aa A; Tasset C; Van't Klooster G
    Clin Pharmacokinet; 2015 Aug; 54(8):859-74. PubMed ID: 25681059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
    El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
    Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
    Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
    Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
    Combe B; Kivitz A; Tanaka Y; van der Heijde D; Simon JA; Baraf HSB; Kumar U; Matzkies F; Bartok B; Ye L; Guo Y; Tasset C; Sundy JS; Jahreis A; Genovese MC; Mozaffarian N; Landewé RBM; Bae SC; Keystone EC; Nash P
    Ann Rheum Dis; 2021 Jul; 80(7):848-858. PubMed ID: 33504485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
    Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
    JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
    Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.